Title: Chief Medical Officer and Executive Vice President
Company: Horizon Therapeutics
Location: Lincolnshire, Illinois, United States
Jeffrey W. Sherman, MD, FACP, Chief Medical Officer and Executive Vice President at Horizon Therapeutics, has been recognized by Marquis Who’s Who Top Doctors for dedication, achievements, and leadership in pharmaceuticals.
With more than 30 years of professional experience, Dr. Sherman has been the chief medical officer and executive vice president of Horizon Therapeutics since 2009, having held the same positions with IDM Pharma from 2007 to 2009. Prior to obtaining these roles, he was vice president of clinical science with Takeda Global Research and Development in 2007, chief medical officer and executive vice president of NeoPharm from 2000 to 2007, and head of oncology global medical operations with Global Medical Marketing and Oncology Franchise in 2000 at Searle/Monsanto. Dr. Sherman currently serves as a Drug Information Association (DIA) liaison to the Clinical Trial Transformation Initiative (CTTI), a public-private partnership founded by the U.S. Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. Furthermore, he is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine.
From 1992 to 1999, Dr. Sherman worked from director of clinical research to executive director of clinical research at Searle/Monsanto, and from 1990 to 1992, he was director of clinical research at the Bristol-Myers Squibb Pharmaceutical Research Institute. Earlier in his career, he was assistant director and associate director of clinical pharmacology at the Squibb Institute of Medical Research from 1988 to 1990 and a research associate with Howard Hughes Medical Institute from 1986 to 1988. Dr. Sherman began his career as a student at Lake Forest College, obtaining a Bachelor of Arts in 1976. He continued his studies with Chicago Medical School, earning a Doctor of Medicine in 1981. He then joined Northwestern University Medical Center as an intern, resident, and chief resident of internal medicine from 1981 to 1985, and he completed a fellowship in infectious diseases at the University of California, San Francisco, from 1985 to 1988. Dr. Sherman is a member of the Global Genes Medical and Scientific Advisory Board and involved with the National Organization for Rare Disorders (NORD) and the European Organisation for Rare Diseases (EURORDIS). Furthermore, he is on the Board of Directors of Strongbridge Biopharma and Xeris Pharmaceuticals.
For more information, please visit:
Contact Dr. Sherman: